Literature DB >> 25033707

The prognostic value of liver tumor T cell infiltrates.

Hadi Khan1, Venu G Pillarisetty2, Steven C Katz3.   

Abstract

Tumor infiltrating lymphocytes (TIL) have been demonstrated to predict oncologic outcomes following resection of primary intrahepatic neoplasms and metastatic liver tumors. Despite strong immunosuppressive factors within the intrahepatic space, TIL are frequently demonstrated in liver tumors. The presence of TIL within liver tumors provides evidence of a host immune response that may be protective, but often is rendered ineffective by tumor induced immune dysfunction. In this review, we discuss techniques involved in studying TIL and subsets of TIL commonly identified. We emphasize the unique nature of the intrahepatic milieu that promotes immunosuppression, and how liver TIL and TIL ratios can be used as indicators of prognosis. Several types of primary and metastatic liver tumors are considered to highlight the similarities and important differences in TIL responses, which likely reflect how intrahepatic immunity is influenced by tumor biology. The studies we discuss indicate that tumor infiltration by suppressor cells and expression of immunoinhibitory molecules by TIL limits the anti-tumor immune function of effector T cells. Most patients fail to mount an adequate immune response to liver tumors, which provides compelling rationale for clinical study of immunotherapy for intrahepatic neoplasms.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunotherapy; Liver tumors; Programmed death-1; T cells; Tumor infiltrating lymphocytes

Mesh:

Year:  2014        PMID: 25033707      PMCID: PMC4134707          DOI: 10.1016/j.jss.2014.06.001

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  42 in total

1.  Tissue microarrays: a new approach for quality control in immunohistochemistry.

Authors:  J Packeisen; H Buerger; R Krech; W Boecker
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

2.  Critical role of spatial interaction between CD8⁺ and Foxp3⁺ cells in human gastric cancer: the distance matters.

Authors:  Anita Feichtenbeiner; Matthias Haas; Maike Büttner; Gerhard G Grabenbauer; Rainer Fietkau; Luitpold V Distel
Journal:  Cancer Immunol Immunother       Date:  2013-10-30       Impact factor: 6.968

3.  Local immune response predicts survival in patients with thick (t4) melanomas.

Authors:  Jessica A Cintolo; Phyllis Gimotty; Anne Blair; Dupont Guerry; David E Elder; Rachel Hammond; Rosalie Elenitsas; Xiaowei Xu; Douglas Fraker; Lynn M Schuchter; Brian J Czerniecki; Giorgos Karakousis
Journal:  Ann Surg Oncol       Date:  2013-07-10       Impact factor: 5.344

Review 4.  Immunotherapy for solid tumors--a review for surgeons.

Authors:  Abdul Saied; Venu G Pillarisetty; Steven C Katz
Journal:  J Surg Res       Date:  2013-12-25       Impact factor: 2.192

5.  Hepatic neuroendocrine metastases: does intervention alter outcomes?

Authors:  R S Chamberlain; D Canes; K T Brown; L Saltz; W Jarnagin; Y Fong; L H Blumgart
Journal:  J Am Coll Surg       Date:  2000-04       Impact factor: 6.113

Review 6.  MHC class I down-regulation: tumour escape from immune surveillance? (review).

Authors:  Jan Bubeník
Journal:  Int J Oncol       Date:  2004-08       Impact factor: 5.650

7.  Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue.

Authors:  Anna M Sherwood; Ryan O Emerson; Dominique Scherer; Nina Habermann; Katharina Buck; Jürgen Staffa; Cindy Desmarais; Niels Halama; Dirk Jaeger; Peter Schirmacher; Esther Herpel; Matthias Kloor; Alexis Ulrich; Martin Schneider; Cornelia M Ulrich; Harlan Robins
Journal:  Cancer Immunol Immunother       Date:  2013-06-16       Impact factor: 6.968

8.  Liver sinusoidal endothelial cells are insufficient to activate T cells.

Authors:  Steven C Katz; Venu G Pillarisetty; Joshua I Bleier; Alaap B Shah; Ronald P DeMatteo
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

9.  Intrahepatic interleukin-17+ T cells and FoxP3+ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma.

Authors:  Yong Huang; Fengmei Wang; Yijun Wang; Zhengyan Zhu; Yingtang Gao; Zhe Ma; Ruicheng Xu; Zhi Du
Journal:  J Gastroenterol Hepatol       Date:  2014-04       Impact factor: 4.029

10.  TNFα and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells.

Authors:  Daniel S Straus
Journal:  Mol Cancer       Date:  2013-07-17       Impact factor: 27.401

View more
  11 in total

1.  Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma.

Authors:  Marco Mina; Renata Boldrini; Arianna Citti; Paolo Romania; Valerio D'Alicandro; Maretta De Ioris; Aurora Castellano; Cesare Furlanello; Franco Locatelli; Doriana Fruci
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

Review 2.  Immunosuppression in liver tumors: opening the portal to effective immunotherapy.

Authors:  P Guha; J Reha; S C Katz
Journal:  Cancer Gene Ther       Date:  2016-12-02       Impact factor: 5.987

3.  Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.

Authors:  M Thorn; P Guha; M Cunetta; N J Espat; G Miller; R P Junghans; S C Katz
Journal:  Cancer Gene Ther       Date:  2016-05-20       Impact factor: 5.987

4.  PLCε1 suppresses tumor growth by regulating murine T cell mobilization.

Authors:  M Strazza; K Adam; A V Smrcka; S Lerrer; A Mor
Journal:  Clin Exp Immunol       Date:  2020-01-09       Impact factor: 4.330

5.  Metastasectomy for Tumor-Infiltrating Lymphocytes: An Emerging Operative Indication in Surgical Oncology.

Authors:  Joseph G Crompton; Nicholas Klemen; Udai S Kammula
Journal:  Ann Surg Oncol       Date:  2017-11-29       Impact factor: 5.344

6.  Tumor-associated immune factors are associated with recurrence and metastasis in non-small cell lung cancer.

Authors:  X Yan; S-C Jiao; G-Q Zhang; Y Guan; J-L Wang
Journal:  Cancer Gene Ther       Date:  2017-01-13       Impact factor: 5.987

Review 7.  Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: A meta-analysis.

Authors:  Wei Ding; Xuezhong Xu; Yan Qian; Wenbo Xue; Yibo Wang; Jianguo Du; Lei Jin; Yulin Tan
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

8.  The role of the immunoescape in colorectal cancer liver metastasis.

Authors:  Chie Takasu; Shoko Yamashita; Yuji Morine; Kozo Yoshikawa; Takuya Tokunaga; Masaaki Nishi; Hideya Kashihara; Toshiaki Yoshimoto; Mitsuo Shimada
Journal:  PLoS One       Date:  2021-11-19       Impact factor: 3.240

Review 9.  Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.

Authors:  Xiaoqiang Yin; Tongchui Wu; Yadong Lan; Wulin Yang
Journal:  Biosci Rep       Date:  2022-02-25       Impact factor: 3.840

Review 10.  Tumor reductive therapies and antitumor immunity.

Authors:  Huiqin Guo; Kangla Tsung
Journal:  Oncotarget       Date:  2017-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.